Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus chemotherapy vs chemotherapy in squamous NSCLC
CTR20181746Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in Pulmonary squamous cell carcinoma, sponsored by Celgene Corporation. Started Nov 2019; status: completed.
02
Drugs
tislelizumab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20181746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181746.